All In Biotech

NDA 208341 · Gilead Sciences INC

Epclusa

Sofosbuvir, Velpatasvir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jun 28, 2016

Approved uses

7

Original approval plus efficacy supplements

Registered trials

343

110 Phase 3, 6 recruiting

FAERS reports

12,830

3,897 serious, 592 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with sofosbuvir and velpatasvir. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed...

What it is approved for

From the label in effect Mar 6, 2025.

Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4 ) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. Sofosbuvir and velpatasvir is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.

Mechanism: Sofosbuvir and velpatasvir tablets (400 mg/100 mg) are a fixed-dose combination of sofosbuvir and velpatasvir, which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 27, 2022 Supplement 19 · Efficacy LabelLetter
  • Jun 10, 2021 Supplement 17 · Efficacy · priority review OrphanLabelLetter
  • Jul 14, 2020 Supplement 15 · Efficacy LabelLetter
  • Mar 19, 2020 Supplement 14 · Efficacy · priority review OrphanLabelLetter
  • Nov 15, 2019 Supplement 12 · Efficacy LetterLabel
  • Aug 1, 2017 Supplement 1 · Efficacy LetterLabel
  • Jun 28, 2016 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyOrphanLabelReviewLetter
2 products under this application
  • EPCLUSA · SOFOSBUVIR 400MG; VELPATASVIR 100MG · TABLET, ORAL · Prescription
  • EPCLUSA · SOFOSBUVIR 200MG; VELPATASVIR 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sofosbuvir" as an intervention, any sponsor and status, largest first.

All 343 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,628
  • headache2,218
  • nausea1,178
  • diarrhoea664
  • drug ineffective558
  • insomnia514
  • hepatitis c413
  • treatment failure337
  • vomiting330
  • death312
  • dizziness287
  • rash259

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2016400
20172,137
20182,222
20192,663
20201,724
20211,071
2022990
2023570
2024449
2025373
2026231

Recalls

1 FDA enforcement reports for this application.

  • Mar 7, 2025 · Class II · Terminated

    Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epclusa (Sofosbuvir/Velpatasvir)

2024 spending

$758M

Beneficiaries

12,242

31,431 claims

Per beneficiary

$61,921

$848.72 per unit

View as table
YearSpending
2020$867,053,907
2021$938,659,922
2022$899,944,724
2023$877,398,115
2024$758,041,570

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 454 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.